Draven Rane
dravenrane.bsky.social
Draven Rane
@dravenrane.bsky.social
Synthetic immunologist @ Enoda
Stanford 2023
Previously @ Stanford’s Qi and Weinacht Labs
Board Member @ Freedom Forward
Harm Reductionist and PHN @ SFAF
Reposted by Draven Rane
Ich habe heute im Deutschlandfunk gehört, dass es erste Schätzungen gibt, dass alleine die Kürzung der internationalen Hilfsgelder durch die faschistische Führung der USA, weltweit für ca. 300.000 Todesfälle verantwortlich ist.

Meine Verachtung für diese Massenmörder ist beispiellos.
May 31, 2025 at 7:47 PM
Reposted by Draven Rane
Manufacturing CAR T cells in the laboratory is expensive and time-consuming.

An in vivo approach could get this powerful therapy to more people
https://go.nature.com/45w5A5w
Cancer-fighting immune cells could soon be engineered inside our bodies
Nature - Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful therapy to more people.
go.nature.com
May 31, 2025 at 3:16 PM
Reposted by Draven Rane
This is what can be achieved today due to longstanding federal support of academic basic science alongside close partnership of universities, private industry and NIH intramural initiatives. An ecosystem worth not just saving but doubling down on!

innovativegenomics.org/news/first-p...
First Patient Treated with Personalized CRISPR Therapy, Developed in Just Six Months
The first on-demand CRISPR therapy for an infant with a rare metabolic disease developed by the IGI and collaborators around the world.
innovativegenomics.org
May 15, 2025 at 5:40 PM
Reposted by Draven Rane
Another article on Indigenous knowledge perspectives. Oh! this is what DIVERSITY means. "We discuss how Two-Eyed Seeing can bring breadth of knowledge and humility to the development of research and clinical practices for brain health. "
#science #philsci
www.nature.com/articles/s41...
Two-Eyed Seeing and other Indigenous perspectives for neuroscience - Nature
Combining Indigenous insights with neuroscience methods through Two-Eyed Seeing can broaden the understanding of brain function and mental wellbeing by merging reductionist and holistic perspectives a...
www.nature.com
May 11, 2025 at 10:47 PM
Reposted by Draven Rane
T cell-specific antigens are discovered at high throughput without killing target cells go.nature.com/3L6cuDp
rdcu.be/ekKtU
High-throughput discovery of MHC class I- and II-restricted T cell epitopes using synthetic cellular circuits - Nature Biotechnology
T cell-specific antigens are discovered at high throughput without killing target cells.
go.nature.com
May 7, 2025 at 12:48 AM
Reposted by Draven Rane
Our perspective in @natrevimmunol.nature.com on new concepts in neuroimmune interactions that have challenged the old dogma that immune privilege is a result of the isolation of the nervous and immune systems.

@jonykipnis.bsky.social
www.nature.com/articles/s41...
Redefining CNS immune privilege - Nature Reviews Immunology
In this Perspective, Smyth and Kipnis reappraise the concept of immune privilege in the central nervous system. Although immune privilege was originally thought to involve isolation of the central ner...
www.nature.com
May 2, 2025 at 8:05 PM
Reposted by Draven Rane
Researchers are studying why mitochondria are moving between cells and whether the process can be harnessed to treat cancer and other diseases

https://go.nature.com/3RcyzDa
Cells are swapping their mitochondria. What does this mean for our health?
Nature - Researchers are studying why the energy factories are moving between cells and whether the process can be harnessed to treat cancer and other diseases.
go.nature.com
April 13, 2025 at 4:16 PM
Reposted by Draven Rane
An immigration crackdown in the United States is rattling the global research community, with high-profile detentions and deportations of academics stoking fears even for travellers with valid entry documents

https://go.nature.com/4iMw7PV
‘Anxiety is palpable’: detention of researchers at US border spurs travel worries
Several high-profile incidents in the past month have scientists on edge.
go.nature.com
March 25, 2025 at 12:48 PM
Reposted by Draven Rane
Unfortunately, there was another round of FUNDED grants cancelled yesterday. These illegal cuts stop projects that have been in progress for years, interrupt lifesaving research, and destroy the public good of science in the US.

If you were impacted, please share you story with us: fedfreeze.org
FedFreeze.org
Fight Trump's funding freeze to protect lifesaving care and research.
fedfreeze.org
March 22, 2025 at 1:09 PM
Reposted by Draven Rane
Another unvaccinated child dies from measles, a fully preventable disease, and only the second child to die from measles in the US in the past 22 years
March 6, 2025 at 10:02 PM
Reposted by Draven Rane
In Brief: Gene and cell therapies from Bayer subsidaries AskBio & BlueRock Therapeutics make headway in trials for Parkinson's nature.com/articles/s41...
rdcu.be/ebozG
Gene and cell therapies for Parkinson’s make headway - Nature Biotechnology
Nature Biotechnology - Gene and cell therapies for Parkinson’s make headway
nature.com
February 26, 2025 at 4:22 PM
Reposted by Draven Rane
What is your pace of aging? A new @nature.com feature on molecular clocks by gets into the issues surrounding these tests (can is really can't) nature.com/articles/d41... by @heidiledford.bsky.social
February 25, 2025 at 6:28 PM
Reposted by Draven Rane
Excited to share this new work led by postdoc Brendan Floyd, deep mapping of cell-surface protein interactomes of T and B cells reveals maverick mitochondrial proteins and immune modulatory complexes.

www.biorxiv.org/content/10.1...
Mapping the nanoscale organization of the human cell surface proteome reveals new functional associations and surface antigen clusters
The cell surface is a dynamic interface that controls cell-cell communication and signal transduction relevant to organ development, homeostasis and repair, immune reactivity, and pathologies driven b...
www.biorxiv.org
February 18, 2025 at 7:27 PM
Reposted by Draven Rane
Society, patients and clinicians welcome a much-needed non-opioid pain medication. Vertex’s first-in-class analgesic Journavx could soon be followed by a new generation of addiction-free pain drugs acting at NaV1.8 sodium channels www.nature.com/articles/s41...
Vertex’s opioid-free drug for acute pain wins FDA approval - Nature Biotechnology
Society, patients and clinicians welcome a much-needed non-opioid pain medication. Vertex’s first-in-class analgesic Journavx could soon be followed by a new generation of addiction-free pain drugs ac...
www.nature.com
February 19, 2025 at 8:33 AM
Reposted by Draven Rane
LAG3 marks activated but hyporesponsive NK cells. https://www.biorxiv.org/content/10.1101/2024.12.18.629184v1
December 22, 2024 at 2:17 AM
Reposted by Draven Rane
Poorly validated antibodies fuel the reproducibility crisis.

YCharOS shares a protocol for antibody validation using KO cell lines.
tinyurl.com/NP-article

Read also the N&V.
tinyurl.com/NP-comment

Glad that our study is cited as an example for improving data quality.
tinyurl.com/CSC-Letter
A consensus platform for antibody characterization - Nature Protocols
YCharOS is a consensus platform for antibody characterization developed through collaboration between academia and industry, enabling direct comparisons among antibodies that target a specific protein...
www.nature.com
December 19, 2024 at 10:06 AM
Reposted by Draven Rane
Thrilled to share our new manuscript combining Perturb-seq (pooled CRISPR screens + scRNA-seq readouts) with Cas12a and its unique guide RNA processing ability.

Led by the extremely talented Valentina Snetkova at Genentech :)!
Have you been interested combining Perturb-Seq screening with Cas12a’s unique capabilities for multiplexed guide RNA expression? Us too! So, we figured out some useful tricks to make that possible, which you can find in our new pre-print. Short thread below: www.biorxiv.org/content/10.1...
Degron-modified Cas12a enhances single-cell CRISPR screening
Single-cell CRISPR (Perturb-seq) screens have primarily relied on Cas9 whereas Cas12a, despite its unique effectiveness for multiplex guide expression, remains underexplored. This may be due to Cas12a...
www.biorxiv.org
December 9, 2024 at 8:35 PM